This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

Principal Results From the Women's Health Initiative Randomized Controlled Trial

Writing Group for the Women's Health Initiative Investigators

JAMA. 2002;288:321-333.

Context  Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain.

Objective  To assess the major health benefits and risks of the most commonly used combined hormone preparation in the United States.

Design  Estrogen plus progestin component of the Women's Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at baseline were recruited by 40 US clinical centers in 1993-1998.

Interventions  Participants received conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n = 8506) or placebo (n = 8102).

Main Outcomes Measures  The primary outcome was coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with invasive breast cancer as the primary adverse outcome. A global index summarizing the balance of risks and benefits included the 2 primary outcomes plus stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes.

Results  On May 31, 2002, after a mean of 5.2 years of follow-up, the data and safety monitoring board recommended stopping the trial of estrogen plus progestin vs placebo because the test statistic for invasive breast cancer exceeded the stopping boundary for this adverse effect and the global index statistic supported risks exceeding benefits. This report includes data on the major clinical outcomes through April 30, 2002. Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with 286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85) with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases; colorectal cancer, 0.63 (0.43-0.92) with 112 cases; endometrial cancer, 0.83 (0.47-1.47) with 47 cases; hip fracture, 0.66 (0.45-0.98) with 106 cases; and death due to other causes, 0.92 (0.74-1.14) with 331 cases. Corresponding HRs (nominal 95% CIs) for composite outcomes were 1.22 (1.09-1.36) for total cardiovascular disease (arterial and venous disease), 1.03 (0.90-1.17) for total cancer, 0.76 (0.69-0.85) for combined fractures, 0.98 (0.82-1.18) for total mortality, and 1.15 (1.03-1.28) for the global index. Absolute excess risks per 10 000 person-years attributable to estrogen plus progestin were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions per 10 000 person-years were 6 fewer colorectal cancers and 5 fewer hip fractures. The absolute excess risk of events included in the global index was 19 per 10 000 person-years.

Conclusions  Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women. All-cause mortality was not affected during the trial. The risk-benefit profile found in this trial is not consistent with the requirements for a viable intervention for primary prevention of chronic diseases, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.

Writing Group for the Women's Health Initiative Investigators: Jacques E. Rossouw, MBChB, MD, National Heart, Lung, and Blood Institute, Bethesda, Md; Garnet L. Anderson, PhD, Ross L. Prentice, PhD, Andrea Z. LaCroix, PhD, and Charles Kooperberg, PhD, Fred Hutchinson Cancer Research Center, Seattle, Wash; Marcia L. Stefanick, PhD, Stanford University Clinical Center, Stanford, Calif; Rebecca D. Jackson, MD, Ohio State University Clinical Center, Columbus; Shirley A. A. Beresford, PhD, Fred Hutchinson Cancer Research Center, Seattle, Wash; Barbara V. Howard, PhD, MedStar Research Institute, Washington, DC; Karen C. Johnson, MD, MPH, University of Tennessee, Memphis; Jane Morley Kotchen, MD, Medical College of Wisconsin, Milwaukee; Judith Ockene, PhD, University of Massachusetts Medical School, Worcester.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTERS

A Woman Attempting to Discontinue Hormone Therapy
Robert R. Freedman, Michael Kleerekoper, and Deborah Grady
JAMA. 2002;288(18):2264-2265.
EXTRACT | FULL TEXT  

Antioxidants and Risk of Alzheimer Disease
Arthur E. Varner, Steven Brenner, Martha Clare Morris, Denis A. Evans, Julia L. Bienias, Christine C. Tangney, David A. Bennett, Neelum Aggarwal, Robert S. Wilson, Paul A. Scherr, Marianne J. Engelhart, and Monique M. B. Breteler
JAMA. 2002;288(18):2265-2266.
EXTRACT | FULL TEXT  

Estrogen Replacement Therapy and Risk of Ovarian Cancer in Postmenopausal Women
Kenneth Burry, Joanna M. Cain, Lucy Gilbert, Srinivasan Krishnamurthy, Seang Lin Tan, Eduardo L. Franco, James V. Lacey, Jr, Pamela J. Mink, Jay H. Lubin, Mark E. Sherman, Rebecca Troisi, Patricia Hartge, Arthur Schatzkin, and Catherine Schairer
JAMA. 2002;288(20):2538-2539.
EXTRACT | FULL TEXT  

Risks of Postmenopausal Hormone Replacement
Nina Radford, Tim Church, Frank E. Speizer, Beverley E. Pearson Murphy, Susan R. Davis, Henry G. Burger, William H. Goodson III, Henk R. Franke, Ishay Lev, Amnon Lahad, Aharon Karni, Eric Brunner, Raanan Gillon, Houston H. Stokes, Edeltraut Garbe, Samy Suissa, Sean I. Savitz, and Lou Caplan
JAMA. 2002;288(22):2819-2824.
EXTRACT | FULL TEXT  

Hormone Replacement Following Early Menopause
Glinda S. Cooper, Suzanne W. Fletcher, and Graham A. Colditz
JAMA. 2002;288(22):2824-2825.
EXTRACT | FULL TEXT  

Relationship Between Hormone Replacement Therapy, Socioeconomic Status, and Coronary Heart Disease
Francine Grodstein and JoAnn E. Manson
JAMA. 2003;289(1):44.
EXTRACT | FULL TEXT  

Research in Medical Education
Rose Hatala and Gordon H. Guyatt
JAMA. 2003;289(2):176.
EXTRACT | FULL TEXT  

Estrogen Replacement and Risk of Alzheimer Disease
Amnon Lahad and Lev Ishay
JAMA. 2003;289(9):1100-1101.
EXTRACT | FULL TEXT  

Estrogen Replacement and Risk of Alzheimer Disease
Lynn Rosenberg
JAMA. 2003;289(9):1101.
EXTRACT | FULL TEXT  

Estrogen Replacement and Risk of Alzheimer Disease—Reply
Peter P. Zandi and John C. S. Breitner
JAMA. 2003;289(9):1101-1102.
EXTRACT | FULL TEXT  

Effects of Estrogen Plus Progestin on Risk of Dementia—Reply
Sally A. Shumaker, Stephen R. Rapp, Mark A. Espeland, Robert B. Wallace, Susan L. Hendrix, Victor W. Henderson, Margery L. Gass, and Leon Thal
JAMA. 2003;290(13):1707-1708.
EXTRACT | FULL TEXT  

Exercise and Risk of Breast Cancer
Harry B. Burke
JAMA. 2003;290(24):3193.
EXTRACT | FULL TEXT  

Effects of Estrogen-Only Treatment in Postmenopausal Women
Vicki F. Meyer
JAMA. 2004;292(6):683-684.
EXTRACT | FULL TEXT  

Effects of Estrogen-Only Treatment in Postmenopausal Women
Karla Kerlikowske and Diana L. Miglioretti
JAMA. 2004;292(6):684-685.
EXTRACT | FULL TEXT  

Effects of Estrogen-Only Treatment in Postmenopausal Women
Katherine L. Brubaker
JAMA. 2004;292(6):686.
EXTRACT | FULL TEXT  

Hormone Therapy and Cardiovascular Risk
Samuel Shapiro
JAMA. 2007;298(6):623.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Failure of Estrogen Plus Progestin Therapy for Prevention
Suzanne W. Fletcher and Graham A. Colditz
JAMA. 2002;288(3):366-368.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Comparative effectiveness research: Relevance and applications to pharmacy
Schumock and Pickard
Am J Health Syst Pharm 2009;66:1278-1286.
ABSTRACT | FULL TEXT  

Trends and determinants of prescription medication use for treatment of osteoporosis
Farley and Blalock
Am J Health Syst Pharm 2009;66:1191-1201.
ABSTRACT | FULL TEXT  

Finally! A Model for Progesterone Receptor Action in Normal Human Breast
Lydon and Edwards
Endocrinology 2009;150:2988-2990.
FULL TEXT  

Ovariectomy and 17{beta}-Estradiol Replacement Do Not Alter {beta}-Amyloid Levels in Sheep Brain
Barron et al.
Endocrinology 2009;150:3228-3236.
ABSTRACT | FULL TEXT  

Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17{beta}-estradiol and norethisterone when compared with an orally administered 17{beta}-estradiol norethisterone regimen
Rozenberg et al.
Hum Reprod 2009;24:1739-1747.
ABSTRACT | FULL TEXT  

Invited Commentary: Hormone Therapy Risks and Benefits--The Women's Health Initiative Findings and the Postmenopausal Estrogen Timing Hypothesis
Banks and Canfell
Am J Epidemiol 2009;170:24-28.
ABSTRACT | FULL TEXT  

Benefits and Risks of Postmenopausal Hormone Therapy When It Is Initiated Soon After Menopause
Prentice et al.
Am J Epidemiol 2009;170:12-23.
ABSTRACT | FULL TEXT  

Cancer Prevention: From 1727 to Milestones of the Past 100 Years
Lippman and Hawk
Cancer Res. 2009;69:5269-5284.
ABSTRACT | FULL TEXT  

Postmenopausal Hypertension: Mechanisms and Therapy
Barton and Meyer
Hypertension 2009;54:11-18.
FULL TEXT  

Postmenopausal Hormone Treatment
Hulley and Grady
JAMA 2009;301:2493-2495.
FULL TEXT  

Newer Antidepressants and Gabapentin for Hot Flashes: An Individual Patient Pooled Analysis
Loprinzi et al.
JCO 2009;27:2831-2837.
ABSTRACT | FULL TEXT  

The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer
Lanari et al.
Endocr Relat Cancer 2009;16:333-350.
ABSTRACT | FULL TEXT  

Success with Men's Educational Group Appointments (MEGA): Subjective Improvements in Patient Education
Campbell et al.
Am J Mens Health 2009;3:173-178.
ABSTRACT  

Low-fat, increased fruit, vegetable, and grain dietary pattern, fractures, and bone mineral density: the Women's Health Initiative Dietary Modification Trial
McTiernan et al.
Am. J. Clin. Nutr. 2009;89:1864-1876.
ABSTRACT | FULL TEXT  

Why should clinicians understand epidemiology?
McAllister and Wild
Postgrad. Med. J. 2009;85:313-315.
ABSTRACT | FULL TEXT  

Herb-related aneuploidy in breast fibroadenoma
Chang et al.
BMJ Case Reports 2009;2009:bcr0920080926-bcr0920080926.
ABSTRACT | FULL TEXT  

Colorectal Cancer in Relation to Postmenopausal Estrogen and Estrogen Plus Progestin in the Women's Health Initiative Clinical Trial and Observational Study
Prentice et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:1531-1537.
ABSTRACT | FULL TEXT  

Diffusion of Breast Cancer Risk Assessment in Primary Care
Guerra et al.
J Am Board Fam Med 2009;22:272-279.
ABSTRACT | FULL TEXT  

The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute?
Howick et al.
JRSM 2009;102:186-194.
FULL TEXT  

Searching for a Safe Analgesic in Patients With Cardiovascular Disease
Solomon
Circ Cardiovasc Qual Outcomes 2009;2:146-147.
FULL TEXT  

Breast cancer in young women and its impact on reproductive function
Hickey et al.
Hum Reprod Update 2009;15:323-339.
ABSTRACT | FULL TEXT  

Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone
Fanciulli et al.
Hum Reprod Update 2009;15:341-358.
ABSTRACT | FULL TEXT  

Perspectives on the soy-breast cancer relation
Messina and Wu
Am. J. Clin. Nutr. 2009;89:1673S-1679S.
ABSTRACT | FULL TEXT  

Changes in Estrogen Receptor, Progesterone Receptor and Her-2/neu Status with Time: Discordance Rates Between Primary and Metastatic Breast Cancer
BROOM et al.
Anticancer Res 2009;29:1557-1562.
ABSTRACT | FULL TEXT  

Short-term Prophylactic Tamoxifen Reduces the Incidence of Antiestrogen-Resistant/Estrogen Receptor-Positive/Progesterone Receptor-Negative Mammary Tumors
Rose-Hellekant et al.
Cancer Prevention Research 2009;2:496-502.
ABSTRACT | FULL TEXT  

Baroreflex sensitivity varies during the rat estrous cycle: role of gonadal steroids
Goldman et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009;296:R1419-R1426.
ABSTRACT | FULL TEXT  

Orally Administered Lactoferrin Preserves Bone Mass and Microarchitecture in Ovariectomized Rats
Guo et al.
J. Nutr. 2009;139:958-964.
ABSTRACT | FULL TEXT  

Cardiovascular Effects of Physiological and Standard Sex Steroid Replacement Regimens in Premature Ovarian Failure
Langrish et al.
Hypertension 2009;53:805-811.
ABSTRACT | FULL TEXT  

When to Start Antiretroviral Therapy -- Ready When You Are?
Sax and Baden
NEJM 2009;360:1897-1899.
FULL TEXT  

Drospirenone in HRT?
DTB 2009;47:41-44.
ABSTRACT | FULL TEXT  

Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease
Hochman et al.
Lupus 2009;18:313-317.
ABSTRACT  

Are Statin Effects Mediated Through, or in Spite of, Their Cholesterol-lowering Action?
Mascitelli et al.
ANGIOLOGY 2009;60:262-263.
 

Childhood Soy Intake and Breast Cancer Risk in Asian American Women
Korde et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:1050-1059.
ABSTRACT | FULL TEXT  

Certain Progestins Prevent the Enhancing Effect of 17{beta}-Estradiol on NO-Mediated Inhibition of Platelet Aggregation by Endothelial Cells
Zerr-Fouineau et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:586-593.
ABSTRACT | FULL TEXT  

Interference of Progestins With Endothelial Actions of Estrogens: A Matter of Glucocorticoid Action or Deprivation?
Arnal et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:441-443.
FULL TEXT  

Estrogen receptor {beta} mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia
Wang et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009;296:R972-R978.
ABSTRACT | FULL TEXT  

Sex Differences in Stroke Epidemiology: A Systematic Review
Appelros et al.
Stroke 2009;40:1082-1090.
ABSTRACT | FULL TEXT  

Age at Natural Menopause and Risk of Ischemic Stroke: The Framingham Heart Study
Lisabeth et al.
Stroke 2009;40:1044-1049.
ABSTRACT | FULL TEXT  

Estrogen Receptor {alpha} Enhances the Rate of Oxidative DNA Damage by Targeting an Equine Estrogen Catechol Metabolite to the Nucleus
Wang et al.
J. Biol. Chem. 2009;284:8633-8642.
ABSTRACT | FULL TEXT  

Comparative Effectiveness Research: The View From the NHLBI
Lauer
J Am Coll Cardiol 2009;53:1084-1086.
FULL TEXT  

Discarding Logic: 2008 Ancel Keys Memorial Lecture
Lauer
Circulation 2009;119:1533-1537.
FULL TEXT  

Landmarks in the History of Cancer Epidemiology
Greenwald and Dunn
Cancer Res. 2009;69:2151-2162.
ABSTRACT | FULL TEXT  

Ramelteon for the treatment of insomnia in menopausal women
Dobkin et al.
Menopause Int 2009;15:13-18.
ABSTRACT | FULL TEXT  

Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK
Lekander et al.
Menopause Int 2009;15:19-25.
ABSTRACT | FULL TEXT  

Prevention, Diagnosis, and Management of Osteoporosis-Related Fracture
Fakih
JAOA: Journal of the American Osteopathic Association 2009;109:191-193.
FULL TEXT  

Private and Public Ageing in the UK: The Transition through the Menopause
Ballard et al.
Current Sociology 2009;57:269-290.
ABSTRACT  

Effects of aglycone genistein in a rat experimental model of postmenopausal metabolic syndrome
Bitto et al.
J Endocrinol 2009;200:367-376.
ABSTRACT | FULL TEXT  

Thrombosis and Antithrombotic Therapy in Women
Bailey et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:284-288.
ABSTRACT | FULL TEXT  

Status of Women in Cardiovascular Clinical Trials
Kim and Menon
Arterioscler. Thromb. Vasc. Bio. 2009;29:279-283.
FULL TEXT  

Prolactin-Growth Factor Crosstalk Reduces Mammary Estrogen Responsiveness Despite Elevated ER{alpha} Expression
Arendt et al.
Am. J. Pathol. 2009;174:1065-1074.
ABSTRACT | FULL TEXT  

Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial: Results of Subgroup Analyses by Age and Other Factors
Collins et al.
Circulation 2009;119:922-930.
ABSTRACT | FULL TEXT  

Overview of clinical research design
Hartung and Touchette
Am J Health Syst Pharm 2009;66:398-408.
ABSTRACT | FULL TEXT  

The transactivating function 1 of estrogen receptor {alpha} is dispensable for the vasculoprotective actions of 17{beta}-estradiol
Billon-Gales et al.
Proc. Natl. Acad. Sci. USA 2009;106:2053-2058.
ABSTRACT | FULL TEXT  

Salivary Sex Hormone Measurement in a National, Population-Based Study of Older Adults
Gavrilova and Lindau
J Gerontol B Psychol Sci Soc Sci 2009;0:gbn028v1-gbn028.
ABSTRACT | FULL TEXT  

Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Chlebowski et al.
NEJM 2009;360:573-587.
ABSTRACT | FULL TEXT  

Primary Ovarian Insufficiency
Nelson
NEJM 2009;360:606-614.
FULL TEXT  

Acupuncture and Auricular Acupressure in Relieving Menopausal Hot Flashes of Bilaterally Ovariectomized Chinese Women: A Randomized Controlled Trial
Zhou et al.
Evid Based Complement Alternat Med 2009;0:nep001v1-nep001.
ABSTRACT | FULL TEXT  

Medical Management of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop
Khan et al.
J. Clin. Endocrinol. Metab. 2009;94:373-381.
ABSTRACT | FULL TEXT  

Prospective cohort study of soy food intake and colorectal cancer risk in women
Yang et al.
Am. J. Clin. Nutr. 2009;89:577-583.
ABSTRACT | FULL TEXT  

Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial
Lucas et al.
Am. J. Clin. Nutr. 2009;89:641-651.
ABSTRACT | FULL TEXT  

A Select Combination of Clinically Relevant Phytoestrogens Enhances Estrogen Receptor {beta}-Binding Selectivity and Neuroprotective Activities in Vitro and in Vivo
Zhao et al.
Endocrinology 2009;150:770-783.
ABSTRACT | FULL TEXT  

Attitudes Toward Postmenopausal Long-Term Hormone Therapy
Kolip et al.
Qual Health Res 2009;19:207-215.
ABSTRACT  

Nuclear matrix binding is critical for progesterone receptor movement into nuclear foci
Graham et al.
FASEB J. 2009;23:546-556.
ABSTRACT | FULL TEXT  

Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women
Rebbeck et al.
Carcinogenesis 2009;30:269-274.
ABSTRACT | FULL TEXT  

Steroid Sulfatase and Estrogen Sulfotransferase in Colon Carcinoma: Regulators of Intratumoral Estrogen Concentrations and Potent Prognostic Factors
Sato et al.
Cancer Res. 2009;69:914-922.
ABSTRACT | FULL TEXT  

Decreased Mammography Utilization in the United States: Why and How Can We Reverse the Trend?
Wolf and Brem
Am. J. Roentgenol. 2009;192:400-402.
ABSTRACT | FULL TEXT  

Use of Hormone Replacement Therapy, 1998-2007: Sustained Impact of the Women's Health Initiative Findings
Silverman and Kokia
The Annals of Pharmacotherapy 2009;43:251-258.
ABSTRACT | FULL TEXT  

Characterization of Antiestrogenic Activity of the Chinese Herb, Prunella vulgaris, Using In Vitro and In Vivo (Mouse Xenograft) Models
Collins et al.
Biol. Reprod. 2009;80:375-383.
ABSTRACT | FULL TEXT  

Sex Hormones Save Our Skin: The Vascular Networking of Estrogen
Werner and Nickenig
Circ. Res. 2009;104:135-137.
FULL TEXT  

Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings
Tannen et al.
BMJ 2009;338:b81-b81.
ABSTRACT | FULL TEXT  

Heart Disease and Stroke Statistics--2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
WRITING GROUP MEMBERS et al.
Circulation 2009;119:e21-e181.
FULL TEXT  

Postmenopausal hormone therapy and subclinical cerebrovascular disease: The WHIMS-MRI Study
Coker et al.
Neurology 2009;72:125-134.
ABSTRACT | FULL TEXT  

Postmenopausal hormone therapy and regional brain volumes: The WHIMS-MRI Study
Resnick et al.
Neurology 2009;72:135-142.
ABSTRACT | FULL TEXT  

Postmenopausal Levels of Endogenous Sex Hormones and Risk of Colorectal Cancer
Clendenen et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:275-281.
ABSTRACT | FULL TEXT  

A Postmenopausal Patient with Tangier Disease Developing Sjogren's Syndrome
MIYACHI et al.
The Journal of Rheumatology 2009;36:208-209.
FULL TEXT  

Reassessing Benefits and Risks of Hormone Therapy
Gass et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2009;3:29-43.
ABSTRACT  

Estradiol increases angiotensin II type 1 receptor in hearts of ovariectomized rats
Ricchiuti et al.
J Endocrinol 2009;200:75-84.
ABSTRACT | FULL TEXT  

Structural Modulation of Oxidative Metabolism in Design of Improved Benzothiophene Selective Estrogen Receptor Modulators
Qin et al.
Drug Metab. Dispos. 2009;37:161-169.
ABSTRACT | FULL TEXT  

A Composite Intronic Element Directs Dynamic Binding of the Progesterone Receptor and GATA-2
Magklara and Smith
Mol. Endocrinol. 2009;23:61-73.
ABSTRACT | FULL TEXT  

Differential Biochemical and Cellular Actions of Premarin Estrogens: Distinct Pharmacology of Bazedoxifene-Conjugated Estrogens Combination
Berrodin et al.
Mol. Endocrinol. 2009;23:74-85.
ABSTRACT | FULL TEXT  

Estrogen Receptor-{beta} as a Potential Target for Colon Cancer Prevention: Chemoprevention of Azoxymethane-Induced Colon Carcinogenesis by Raloxifene in F344 Rats
Janakiram et al.
Cancer Prevention Research 2009;2:52-59.
ABSTRACT | FULL TEXT  

The Potential Role of Glucose Transport Changes in Hot Flash Physiology: A Hypothesis
Dormire
Biol Res Nurs 2009;10:241-247.
ABSTRACT  

Estradiol Increases IL-8 Secretion of Normal Human Breast Tissue and Breast Cancer In Vivo
Bendrik and Dabrosin
J. Immunol. 2009;182:371-378.
ABSTRACT | FULL TEXT  

Secondary Prevention of Atherothrombotic Events After Ischemic Stroke
Adams
Mayo Clin Proc. 2009;84:43-51.
ABSTRACT | FULL TEXT  

Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease
Mosca et al.
Stroke 2009;40:147-155.
ABSTRACT | FULL TEXT  

Update on JAMA-EXPRESS: Rapid Review and Publication
Fontanarosa and DeAngelis
JAMA 2008;300:2920-2921.
FULL TEXT